Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: Still important in the era of direct acting antiviral therapy?

F. K.F. Cheng, D. M. Torres, S. A. Harrison*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) have an individual prevalence of 1.8-3% and at least 30%, respectively, in the United States. It is therefore not surprising that there is overlap between these two common chronic liver diseases, although the relationship appears to go beyond isolated co-existence. Hepatic steatosis is a common feature of CHC infection and can be related to both metabolic and viral specific factors. Steatosis in the setting of nongenotype 3 CHC has been predictive of response to therapy prior to the advent of the direct acting antiviral medications (DAAs). Similarly, lipid metabolism appears important in response to CHC treatment. The pathways for both lipid homeostasis and NAFLD as it pertains to CHC infection as well as the utilization of statin therapy in CHC infection will be reviewed with a focus on the relevance of these topics in the era of DAA therapy.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalJournal of Viral Hepatitis
Volume21
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Keywords

  • NAFLD
  • cholesterol
  • hepatitis C
  • lipid metabolism
  • statins

Fingerprint

Dive into the research topics of 'Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: Still important in the era of direct acting antiviral therapy?'. Together they form a unique fingerprint.

Cite this